Lead Product(s) : P014
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Quan Capital
Deal Size : $46.0 million
Deal Type : Financing
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
Details : Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.
Product Name : P014
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 11, 2020
Lead Product(s) : P014
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Quan Capital
Deal Size : $46.0 million
Deal Type : Financing